Advertisement
Australia markets open in 2 hours 15 minutes
  • ALL ORDS

    8,132.10
    +49.80 (+0.62%)
     
  • AUD/USD

    0.6670
    -0.0025 (-0.38%)
     
  • ASX 200

    7,863.70
    +49.30 (+0.63%)
     
  • OIL

    79.65
    -0.41 (-0.51%)
     
  • GOLD

    2,430.30
    +12.90 (+0.53%)
     
  • Bitcoin AUD

    103,666.30
    +4,479.24 (+4.52%)
     
  • CMC Crypto 200

    1,467.01
    +112.60 (+8.31%)
     

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOMERVILLE, Mass., April 11, 2024--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of 102,700 restricted stock units ("RSUs") to twelve newly hired employees with a grant date of April 9, 2024 (the "Inducement Grants"). The Inducement Grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2021 Inducement Plan.

The RSUs approved under the Inducement Grants vest equally over four years, with 25% vesting each year on the anniversary of the vesting date.

The Company granted the RSUs as inducement materials to each individual entering into employment with bluebird bio, Inc. in accordance with NASDAQ Listing Rule 5635(c)(4).

ADVERTISEMENT

About bluebird bio, Inc.

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.

With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

bluebird continues to forge new paths as a standalone commercial gene therapy company, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240411929911/en/

Contacts

Investors:
Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com

Media:
Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com